Adicet Bio, Inc. (0HX7.L)
USD 0.67
(7.34%)
USD 0.67
(7.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -142.65 Million USD | -104.41% |
| 2022 | -69.79 Million USD | -12.57% |
| 2021 | -61.99 Million USD | -69.04% |
| 2020 | -36.67 Million USD | -30.35% |
| 2019 | -28.13 Million USD | 25.19% |
| 2018 | -37.61 Million USD | -11.36% |
| 2017 | -33.77 Million USD | -3377700.0% |
| 2016 | -1000.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -29.9 Million USD | -6.73% |
| 2024 Q1 | -28.01 Million USD | 5.0% |
| 2023 Q1 | -30.88 Million USD | -3.37% |
| 2023 FY | -142.65 Million USD | -104.41% |
| 2023 Q4 | -29.48 Million USD | 40.89% |
| 2023 Q3 | -49.88 Million USD | -53.95% |
| 2023 Q2 | -32.4 Million USD | -4.93% |
| 2022 FY | -69.79 Million USD | -12.57% |
| 2022 Q4 | -29.87 Million USD | -35.82% |
| 2022 Q2 | -22.53 Million USD | -588.05% |
| 2022 Q1 | 4.61 Million USD | 129.2% |
| 2022 Q3 | -21.99 Million USD | 2.4% |
| 2021 FY | -61.99 Million USD | -69.04% |
| 2021 Q2 | -10.85 Million USD | 49.09% |
| 2021 Q4 | -15.81 Million USD | -12.85% |
| 2021 Q1 | -21.31 Million USD | -137.99% |
| 2021 Q3 | -14.01 Million USD | -29.1% |
| 2020 Q2 | -8.45 Million USD | -88.48% |
| 2020 Q1 | -4.48 Million USD | 31.8% |
| 2020 FY | -36.67 Million USD | -30.35% |
| 2020 Q4 | -8.95 Million USD | 39.39% |
| 2020 Q3 | -14.77 Million USD | -74.8% |
| 2019 Q3 | -14.77 Million USD | -457.45% |
| 2019 FY | -28.13 Million USD | 25.19% |
| 2019 Q1 | -4.13 Million USD | 0.0% |
| 2019 Q2 | -2.65 Million USD | 35.83% |
| 2019 Q4 | -6.57 Million USD | 55.49% |
| 2018 FY | -37.61 Million USD | -11.36% |
| 2017 FY | -33.77 Million USD | -3377700.0% |
| 2016 FY | -1000.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 53.754% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -163.265% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -61.23% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 59.482% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 48.336% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -20.373% |
| Imunon, Inc. | -19.51 Million USD | -631.018% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2132.869% |
| Editas Medicine, Inc. | -153.21 Million USD | 6.893% |
| FibroGen, Inc. | -284.23 Million USD | 49.809% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 67.872% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -238.06% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 157.132% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 73.384% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 10940.274% |
| Verastem, Inc. | -87.36 Million USD | -63.286% |
| Zoetis Inc. | 2.34 Billion USD | 106.086% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 103.941% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 44.67% |
| Homology Medicines, Inc. | -53.74 Million USD | -165.445% |
| Nektar Therapeutics | -276.05 Million USD | 48.323% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -66.084% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -257.898% |
| Perrigo Company plc | -12.7 Million USD | -1023.291% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 31.823% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.348% |
| Illumina, Inc. | -1.16 Billion USD | 87.712% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 102.38% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 110.505% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -29.033% |
| Waters Corporation | 642.23 Million USD | 122.213% |
| Biogen Inc. | 1.16 Billion USD | 112.286% |
| Evolus, Inc. | -61.68 Million USD | -131.269% |
| bluebird bio, Inc. | -211.91 Million USD | 32.681% |
| Geron Corporation | -184.12 Million USD | 22.522% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 67.596% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 5.888% |
| Myriad Genetics, Inc. | -112 Million USD | -27.373% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 70.353% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 118.086% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -219.837% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 185.095% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 103.608% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 111.505% |
| OPKO Health, Inc. | -188.86 Million USD | 24.465% |
| Exelixis, Inc. | 207.76 Million USD | 168.663% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 234.406% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -200.301% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 40.37% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 61.053% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 150.661% |
| Blueprint Medicines Corporation | -506.98 Million USD | 71.861% |
| Insmed Incorporated | -749.56 Million USD | 80.968% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1225.773% |
| Incyte Corporation | 597.59 Million USD | 123.872% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 81.242% |